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Abstract
Introduction: The rapid development of modern imaging techniques, has led to
an increase in accidentally discovered adrenal masses without clinically appar-
ent hormonal abnormalities. Such tumours have been termed “incidentalomas”.
The diagnostic work-up in patients with adrenal incidentalomas is aimed at the
determination of hormonal activity of the tumour and identification of patients
with potentially malignant tumours. The aim of our study was a retrospective
analysis of selected clinical characteristics and hormonal studies in accidental-
ly discovered adrenal tumours.
Material and methods: Fourty hundred sixty-three patients with serendipitously
discovered adrenal masses, diagnosed and treated in the Department of
Endocrinology and Internal Diseases, Medical University of Gdansk as well as
in the affiliated Endocrinology Clinic between 1993 and October of 2009 were
included in the analysis. Out of all patients, 245 were referred for adrenalectomy. 
Results: We found that clinically “silent” tumours often demonstrate subclini-
cal hormonal activity. In our report, increased 24-h urinary excretion of cortisol
correlated positively with tumour size (p < 0.001). Moreover, a statistical rela-
tionship was demonstrated between tumour size and serum cortisol concen-
tration assessed in the 1 mg dexamethasone suppression test (p < 0.001).
Increased values of dehydroepiandrosterone/dehydroepiandrosterone sulphate
were more often found in malignant than in benign tumours (p < 0.01). Urinary
concentrations of 17-ketosteroids correlate positively with diagnosis of adreno-
cortical cancer (p = 0.02).
Conclusions: We found that clinically “silent” tumours often demonstrate sub-
clinical hormonal activity (subclinical Cushing syndrome, subclinical pheochro-
mocytoma, low-symptomatic adrenocortical cancer).
Key words: adrenal incidentaloma, subclinical Cushing syndrome, subclinical Conn
syndrome, subclinical pheochromocytoma, low-symptomatic adrenocortical cancer.
Introduction
An incidentally discovered adrenal tumour (incidentaloma) is a mass in
one or both adrenal glands detected accidentally during an imaging study
performed for other reasons [1-3].
By definition, incidentalomas do not have prominent clinical symptoms
but can demonstrate low-level activity of the respective hormones, termed
sub- or preclinical syndromes. The first step in the diagnostic work-up of
adrenal incidentalomas is the assessment of their hormonal activity [4-7].
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There have been several attempts at determining
the usefulness of individual laboratory assays in the
work-up of adrenal incidentalomas [4, 6, 8]. 
The aim of our study was to perform a retro-
spective analysis of selected clinical characteristics
and hormonal studies in accidentally discovered
adrenal tumours. The study intended to establish
parameters that could be used to determine the
need for surgery or clinical follow-up only.
Material and methods
Between 1993 and October of 2009, 463 patients
with adrenal incidentalomas were diagnosed and
treated in the Department of Endocrinology and
Internal Diseases, Medical University of Gdansk as
well as in the affiliated outpatient clinic. This group
consisted of 325 female (70.2%) and 138 male
(29.8%) patients aged 19 years to 83 years (mean
age 57.8 ±12.7 years). The patients were referred
because of an adrenal tumour discovered during an
ultrasound examination of the abdomen, performed
for reasons other than a suspected adrenal lesion.
The ultrasound findings were verified by abdomi-
nal computed tomography (CT) and/or magnetic
resonance imaging (MRI). 
The following were regarded as indications for
surgery: tumour size ≥ 4 cm (until 2004, ≥ 3 cm),
increasing tumour size during follow-up and/or
abnormalities of adrenal hormonal function, or find-
ings on imaging studies suggestive of malignancy.
Several patients with adrenal masses smaller than
3 cm and without hormonal activity were referred
for surgery because of their young age and severe
anxiety.
Adrenalectomy was performed in 245 patients.
The remaining 218 patients with smaller tumours
without hormonal activity underwent periodic
assessment of adrenal function and tumour size
with CT (every 6-12 months). All patients are still
being followed by the Endocrinology Outpatient
Clinic (duration of follow-up 1 years to 15 years,
mean duration 8 years).
Hormonal assays and serum biochemistry
In all patients, after obtaining detailed history,
adrenocortical function was assessed by the deter-
mination of serum cortisol and dehydroepiandros-
terone (DHEA) or dehydroepiandrosterone sulphate
(DHEAS). Twenty-four-h urine was also collected for
free cortisol, 17-ketosteroids (17-KS) and 17-hydrox-
ysteroids (17-OHS). A 1 mg overnight dexametha-
sone suppression test was also performed. The
excretion of vanillyl mandelic acid (VMA) and/or
metanephrines in 24-h urine was measured as indi-
cators of adrenal medullary function. Serum elec-
trolytes and glucose were checked in all patients.
In all cases of hypokalaemia, urinary excretion of
potassium was determined. Blood pressure and
heart rate were also recorded. 
Serum cortisol was measured at 8 a.m. and 
8 p.m. in a stress-free environment, and blood sam-
ples were immediately delivered to the laboratory.
The diagnosis of subclinical Cushing syndrome
(SCS) was made when the concentration of corti-
sol after dexamethasone administration was 
> 140 nmol/l. The above assessments were per-
formed with the IMMULITE system by DPC. The
morning serum DHEA and DHEAS concentrations
were determined with a radioimmunological assay
(RIA) using commercial DHEA/DHEAS kits by
IMMUNOTECH and Orion Diagnostica, respective-
ly. 24-h urinary cortisol was determined by RIA
using commercial SPECTRIA Cortisol RIA kits by Ori-
on Diagnostica. The colorimetric method (Zimmer-
mann reaction with m-dinitrobenzene) was used
for the measurement of urinary 17-ketosteroids. 17-
OHS were detected with the colorimetric method
by Porter-Silber. Colour intensity was proportional
to the concentration of hydroxysteroids. Vanillyl
mandelic acid and metanephrines in 24-h urine
were determined by RIA using commercial kits by
Bio-Rad. 
Statistical analysis
The measures of central tendency were com-
pared using Studen’s t test for normally distributed
variables (after logarithmic transformation if appro-
priate) or Mann-Whitney U test for the remaining
variables. The dependencies between nominal vari-
ables as well as contingency tables were analysed
using Pearson's χ2 or Fisher's exact test. A two-
tailed significance level of < 0.05 was regarded as
statistically significant. All statistical analysis was
undertaken with the Statistica 8.0 software (Stat-
Soft, Inc., Tulsa, OK, USA; licensed for the Medical
University of Gdansk).
Results
In the entire group of 463 patients, SCS was
diagnosed in 31 (6.7%) and subclinical pheochro-
mocytoma (PHEO) in 37 patients (8.5%). Not a sin-
gle patient was diagnosed with subclinical Conn
syndrome. Adrenocortical cancer was diagnosed in
12 surgically treated patients with incidentally dis-
covered adrenal masses (4.7%).
The usefulness of urinary vanillyl mandelic
acid and metanephrines in the diagnosis of
pheochromocytoma
Twenty-four-h urinary VMA excretion was meas-
ured preoperatively in 86 out of 245 surgically treat-
ed patients with incidentaloma, including 14 pa  -
tients with PHEO. In PHEO patients, increased 24-h
urinary excretion of VMA was significantly more fre-Arch Med Sci 1, February / 2012 99
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quent than in patients with other adrenal tumours
(p = 0.012). The sensitivity of this parameter cal-
culated in a group of 86 patients was 57%, and
specificity was 77% (Table I).
Twenty-four-h urinary excretion of meta  nephrines
was measured preoperatively in 93 out of 245 surgi  -
cally treated patients with incidentalomas, including
24 patients with PHEO. In patients with pheo  chro-
mocytoma, increased concentration of me  ta  ne  -
phrines was more common than in patients with
other pathological diagnoses. This difference was
statistically significant (p = 0.001). The sensitivity of
this parameter calculated in a group of 93 patients
was 71%, with 86% specificity (Table I).
Serum concentration of DHEA/DHEA-S in
benign and malignant adrenal lesions
Out of 245 patients with surgically treated inci-
dentalomas (including 25 malignant tumours: 
12 adrenocortical cancers, 5 malignant pheochro-
mocytomas and 8 adrenal metastases), the preop-
erative concentration of DHEAS was determined in
35 patients (30 female, 5 male) and that of DHEA
in 143 patients (102 female, 41 male). In 97% of
patients with a benign adrenal mass, serum
DHEA/DHEAS concentrations were within or below
the age- and gender-specific reference range (low
in 78% of cases, normal in 19%). Increased con-
centrations of these hormones were noted in only
3% of benign lesions. 
Serum DHEA/DHEAS concentrations exceeded
the age- and gender-specific reference range in 25%
of patients with malignant adrenal tumours, and
were normal or low in 75% of cases (normal in 31%
of cases, low in 44% of cases). In all cases of
adrenocortical carcinomas, the concentrations of
DHEA/DHEAS were either normal or above the ref-
erence range. All patients with adrenal metastases
had DHEA/DHEAS levels below the reference range.
In conclusion, increased values of DHEA/DHEAS
were more often found in malignant (25%) than in
benign tumours (3%). This correlation was statisti-
cally significant (p < 0.01). Conversely, DHEA/DHEAS
concentrations below the reference range were
more common in patients with benign diseases
(78%) than those with malignancy (44%). This cor-
relation was also statistically significant (p = 0.017)
(Table I).
Urinary 17-ketosteroids in benign 
and malignant adrenal lesions
Twenty-four-h urinary excretion of 17-ketos-
teroids was measured preoperatively in 164 out of
245 surgically treated patients with incidentaloma.
The urinary excretion of 17-ketosteroids exceeded
the upper reference limit in 91% of patients with
adrenocortical carcinoma. In contrast, increased uri-
nary excretion of 17-ketosteroids was found in only
58% of patients without the diagnosis of adreno-
cortical carcinoma. This difference was statistical-
ly significant (p = 0.02) (Table I). 
Morning serum cortisol after the 
administration of dexamethasone
(“overnight” test) and urinary cortisol 
excretion and size of adrenal tumour
Serum cortisol concentration in the dexam-
ethasone test was measured in 314 out of 463 pa-
tients with incidentaloma. In the study group we
found a relatively strong correlation between
tumour size and the serum concentration of corti-
sol after the administration of dexamethasone 
(r = 0.42). This correlation was statistically signifi-
cant (p < 0.001) (Figure 1). Similarly, in 373 out of
463 patients with incidentaloma, a strong correla-
Urine VMAP heochromocytoma Other adrenal tumours Value of p
Elevated 57.1% 23.3% 0.012
Normal 42.9% 76.7%
Urine methoxycatecholamines Pheochromocytoma Other adrenal tumours Value of p
Elevated 70.8% 8.6% < 0.001
Normal 29.2% 91.4%
Serum DHEA(S) Malignant tumours Benign adrenal tumours Value of p
Elevated 25% 3% 0.017
Normal 31% 19%
Below normal 44% 78%
Urine 17-ketosteroids Adrenocortical cancer Other adrenal tumours Value of p
Elevated 91% 58% 0.020
Normal 9% 42%
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tion was found between tumour size and the 
24-h urinary excretion of cortisol. This correlation
was also statistically significant (p < 0.001) (Figure 1). 
Discussion
The diagnostic work-up of adrenal incidentalo-
mas is aimed at detection of malignancy (primary
or metastatic) or subclinical hormonal hyperactiv-
ity. Establishing benign character of an inciden-
taloma provides reassurance to the patient and
decreases the costs of follow-up studies. Therefore,
many authors have tried to determine imaging and
laboratory criteria for malignancy in adrenal inci-
dentalomas [2, 4]. 
Tumours with biochemically confirmed increased
secretion of cortisol, mineralocorticoids, androgens
or catecholamines should be treated surgically.
Thus, many authors recommend an array of hor-
monal assays in patients with adrenal incidentalo-
mas. Most are not hormonally active but approxi-
mately 15% demonstrate hypersecretion of
medullary or cortical hormones, especially with
bilateral lesions [9]. 
Subclinical Cushing syndrome (SCS) is the most
common hormonal abnormality, being found in 
5% to 8% of patients with incidentalomas, accord-
ing to different authors [6, 10]. 
Impaired suppression of cortisol secretion with
dexamethasone occurs earlier than the increase in
the urinary excretion of free cortisol and its metabo-
lites. The low-dose dexamethasone suppression
test, regarded as a screening test, is considered to
be the best diagnostic parameter in SCS, yielding
abnormal results in as many as 80% of patients [3].
According to most authors, the morning serum con-
centration of cortisol after dexamethasone admin-
istration above 140 nmol/l (> 3 μg/dl) permits the
diagnosis of SCS [3, 4, 11]. Conversely, serum corti-
sol below 50 nmol/l (< 1.8 μg/dl) excludes subclin-
ical as well as overt Cushing syndrome [11]. Con-
centrations between 50 nmol/l and 140 nmol/l 
(1-3 μg/dl) reflect low-level hormonal activity of the
tumour [11]. Low serum adrenocorticotropic hor-
mone (ACTH) concentrations in the morning hours
were observed in 78% of patients with SCS [5, 12].
On the other hand, increased 24-h urinary excre-
tion of cortisol was demonstrated in 64% of SCS
cases, and low DHEAS levels in only 50% of cases
[9, 13].
The frequency of SCS diagnosis depends on the
number and sensitivity of hormonal assays
employed to assess the function of the pituitary-
adrenal axis. In the presented material, lack of sup-
pression in the 1 mg dexamethasone test was
regarded as the most important parameter estab-
lishing the diagnosis of SCS. Subclinical Cushing
syndrome was diagnosed if the morning serum cor-
tisol concentration exceeded 140 nmol/l. The diag-
nosis of SCS was made in 31 patients, making up
6.7% of all patients in whom the test was per-
formed. 
In some reports, increased 24-h urinary excre-
tion of cortisol correlated positively with tumour
size [6, 14]. In our group of patients, this correlation
was statistically significant (p < 0.001). Moreover,
a statistical relationship was demonstrated
between tumour size and the serum cortisol con-
centration assessed in the 1 mg dexamethasone
suppression test (p < 0.001). 
Most cases of SCS are caused by an adenoma
or bilateral adrenocortical hyperplasia [2, 9]. Adreno-
cortical carcinomas presenting as SCS or virilization
syndrome have also been reported [7]. In our own
material, out of 26 patients with preoperative diag-
nosis of SCS undergoing adrenalectomy (5 other
patients with SCS were not treated surgically
because of lack of consent, severe medical deteri-
oration or advanced age), an adenoma of the adre-
nal cortex was diagnosed in 50% of cases (13/26),
adrenocortical carcinoma in 26.9% of cases (7/26),
nodular hyperplasia of the adrenal cortex in 15.4%
of cases (4/26) and pheochromocytoma in 7.7% of
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Figure 1. Correlations between adrenal tumour size and serum cortisol after 1 mg of dexamethasone overnight (A)
and urine daily excretion of cortisol (B)
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cases (2/26). The granules of adrenomedullary cells
secrete, besides catecholamines, several active pep-
tides, including ACTH and corticotropin-releasing
hormone (CRH) [15]. Oversecretion of these may be
responsible for the development of SCS in two of
our patients with PHEO. 
The clinical signs accompanying hormonal
changes in SCS are subtle or absent. Patients with
SCS, more often than those without, are found to
have hypertension (29 to 92% of cases), type 2 dia-
betes (14 to 42% of cases), obesity (43 to 67% of
cases) and lipid abnormalities (28% of cases) [16,
17]. The low-level secretion of glucocorticoids by
adrenal incidentalomas can be a risk factor for car-
diovascular disease and osteoporosis [16, 18]. The
reports discussed above demonstrate that SCS is
not entirely asymptomatic [12, 16]. In our group of
patients with incidentalomas, we assessed the
prevalence of concomitant type 2 diabetes and
hypertension, but the results were not statistically
significant. 
The possible development of a clinically symp-
tomatic Cushing syndrome determines further
management of patients with SCS. According to
some authors, the likelihood of such development
can be as high as 17% [19]. In contrast, in a study
by Libe, none of the 12 patients with SCS developed
overt CS during 25.5 months of follow-up [20]. At
the same time, a gradual increase in hormonal
activity, even in the absence of recognized criteria
for CS, can be a sign of progression towards this
condition [20]. In our own material, none of the 
5 patients with the diagnosis of PCS who did not
undergo adrenalectomy developed clinically symp-
tomatic Cushing syndrome.
A previously hormonally inactive tumour may,
over time, demonstrate subclinical hypersecretion
of cortisol, fulfilling the criteria for PCS [19]. In our
study group, this transition occurred in two cases.
In both of these patients, signs of progression in
the hormonal assays were associated with increas-
ing tumour size on imaging studies. Both patients
were referred for surgery. 
Among patients with incidentalomas and sub-
clinical Conn syndrome, hypertension was report-
ed in 1.5-3.3% of cases [11, 13, 21]. In this group,
beside hypertension, the remarkable finding was
the borderline low potassium concentration in 60%
up to 84% of cases [11, 13, 21]. On the other hand,
normokalaemia is found in 7% to 38% of patients
with Conn syndrome. This phenomenon is usually
explained by sodium depletion leading to potassi-
um retention, minimizing hypokalaemia [13].
Excellent diagnostic tests are the serum aldos-
terone concentration and serum renin activity (SRA),
both at baseline and after stimulation [15]. In our
study, while the serum potassium concentration
was normal in all cases, aldosterone and SRA were
not measured. This is probably the reason why no
cases of subclinical hyperaldosteronism were diag-
nosed. 
The likelihood of PHEO in a patient with adrenal
incidentaloma is low, at 1.5% to 11% [15]. On the
other hand, as many as 10-20% of these tumours
are detected incidentally [9, 15]. In our group of
patients with incidentaloma, pheochromocytoma
was diagnosed in 8.5% of cases. Pheochromocy-
tomas are characterised by variable hormonal activ-
ity, depending on their size. Small tumours are usu-
ally more active, which translates into secreting
larger amounts of catecholamines into the blood
stream. Based on our material, no statistically sig-
nificant correlation was found between the size of
a PHEO and the 24-h urinary secretion of VMA and
metanephrines.
The serum concentration of metanephrines has
been found to correlate with the overproduction of
catecholamines in tumour tissue [11, 15]. Another
very useful and widely available test is the meas-
urement of 24-h urinary metanephrines (sensitivi-
ty 86%, specificity 97%). The widely used assess-
ment of 24-h urinary VMA should not be
recommended in suspected PHEO because of the
low sensitivity (under 50%) [3]. In our material, the
sensitivity of VMA assessment in the diagnosis of
PHEO was 57%, with 77% specificity. These values
were similar to those found in the current litera-
ture. On the other hand, the sensitivity of deter-
mination of 24-h urinary metanephrines was 71%,
with 86% specificity – values only slightly lower
than those reported in the literature [13]. 
Many studies show that 3% to 10% (seldom
20%) of all PHEOs prove to be malignant [15, 22].
In our material, malignant PHEOs (based on the
presence of distant metastases) were diagnosed in
13.5% of cases (5/37). The slightly higher, compared
to data from the literature, percentage of patients
with malignant tumours can probably be explained
by the relatively small number of patients. It should
be stressed that there are no definite histopatho-
logical criteria for malignant PHEO, and the diag-
nosis is based on the presence of distant metas-
tases in organs that do not normally contain
chromaffin tissue. Hypertension was more common
in patients with benign pheochromocytomas com-
pared with malignant PHEOs; this difference was
statistically significant (p = 0.02). Patients with
malignant PHEOs are more often found to have
increased dihydroxyphenylalanine (DOPA) levels,
and it is the hypotensive effect of DOPA that is
regarded as the possible explanation of normal
blood pressures in this subset of patients. 
Carcinoma of the adrenal cortex is found with
varying frequency in patients with adrenal inci-
dentalomas (usually 5%) and it more commonly
affects females [23]. Nearly 50% of incidentally dis-
covered carcinomas of the adrenal cortex are not102 Arch Med Sci 1, February / 2012
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hormonally active. In hormonally active adrenocor-
tical carcinomas, the concomitant secretion of both
cortisol and androgens has been observed [6, 23].
Carcinomas of the adrenal cortex are usually large
tumours, measuring over 4 cm in diameter. In 20%
to 50% of cases, distant metastases are already
present at the time of diagnosis [2, 6, 23, 24].
Undoubtedly, the size of the adrenal incidentaloma
is a risk factor for the presence of malignancy, but
size alone does not absolutely determine its char-
acter. 
The large production of DHEAS due to hypertro-
phy of the zona reticularis can often suggest the
diagnosis of adrenocortical carcinoma. The con-
centration of DHEA/DHEAS is increased or at the
upper limit of normal in more than 90% of cases
of adrenocortical carcinoma and is, beside the uri-
nary 17-ketosteroids, the second sensitive marker
of this neoplasm [14]. Terzolo et al. demonstrated
that low (41%) or normal (59%) serum concentra-
tions of DHEAS were associated with the patho-
logical diagnosis of a benign adrenal lesion [12]. On
the other hand, results obtained by Bencsik et al.
were less promising [8]. In as many as half of 
12 patients with malignant neoplasms of the adre-
nal glands, the concentrations of DHEAS were
below the reference range. In our own material,
high concentrations of DHEA/DHEAS were more
often found in malignant (25%) than benign (3%)
adrenal tumours. This difference was statistically
significant (p < 0.01). In all cases of adrenocortical
carcinomas, the concentrations of DHEA/DHEAS
were either normal or above the reference range.
Conversely, concentrations of DHEA/DHEAS below
the reference range were associated with a benign
lesion in 78% of cases. The usefulness of DHEAS is
limited by the difficulty in distinguishing lower con-
centrations due to a benign tumour or due to the
physiologically decreased function of the gland in
the elderly.
In cases of subclinical androgen excess that
may accompany accidentally discovered adreno-
cortical carcinomas, increased excretion of andro-
gen metabolites in the 24-h urine is typical.
Increased urinary 17-ketosteroids, alongside
increased serum androgens, are a sensitive mark-
er for this neoplasm [1, 2]. In our own material, 
17-ketosteroids exceeded the upper reference lim-
it in 91% of patients with adrenocortical carcino-
ma. On the other hand, only 58% of patients with
pathologically confirmed benign lesions had con-
centrations of 17-ketosteroids above the upper lim-
it of normal. This difference was statistically sig-
nificant (p = 0.02). 
Most authors suggest that the prognosis in
adrenocortical carcinomas does not depend on their
hormonal activity. Others believe that the presence
of hormonal activity improves survival in this type
of cancer [6, 23]. Among our patients treated sur-
gically for adrenocortical cancer, 12 had inciden-
talomas (4.7%). Most patients had subclinical hor-
monal activity in the form of SCS (26.9%) and
increased adrenal androgen production as deter-
mined by the level of urinary 17-ketosteroids (91%).
Five patients died within a few months after diag-
nosis, 4 are being treated with mitotane, and 
3 were lost to follow-up. 
Malignant adrenal tumours carry a poor prog-
nosis. The 5-year survival rate in adrenocortical car-
cinoma ranges from 32% to 45% [6, 23], whereas
the mean survival in malignant PHEOs is only 28
months [25]. Thus, early diagnosis and appropriate
treatment increase the patient's chance of cure.
Further research in large groups of patients can
help establish new prognostic parameters and the
optimal management of these tumours.
In conclusion, clinically “silent” incidentalomas
are often associated with subclinical hormonal
activity (subclinical Cushing’s syndrome or sub-
clinical pheochromocytoma). Such patients should
undergo surgery regardless of tumour size.
High urinary concentrations of 17-ketosteroids
correlate positively with the diagnosis of adreno-
cortical carcinoma. 
High serum concentrations of DHEA/DHEAS cor-
relate positively with the diagnosis of a malignant
adrenal tumour, whereas DHEA/DHEAS concentra-
tions below the age- and gender-specific reference
range are more common in patients with benign
diseases. 
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